Joshua Weinger

ID: 1b83d53a-2619-30fb-68c4

/

Unclaimed

/

Organization: Goodwin Procter

Regeneron v. Mylan – Update on Aflibercept BPCIA Litigation

Big Molecule Watch · April 18, 2023

Aflibercept IPRs Update

Big Molecule Watch · March 15, 2023

FDA Approves Amgen’s RIABNI™ (Rituximab-arrx) for Adults With Moderate to Severe Rheumatoid Arthritis

Big Molecule Watch · June 10, 2022

Regeneron’s Disclaimer of Aflibercept Formulation Patent Causes PTAB Denial of Institution of Celltrion PGR

Big Molecule Watch · April 6, 2022

Celltrion Announces Agreement with Brazilian Government to Supply Infliximab Biosimilar

Big Molecule Watch · April 1, 2022